Certain Cabinet X-Ray and Optical Camera Systems and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation Based on Consent Order Stipulations; Issuance of Consent Orders; Termination of the Investigation, 13468 [2023-04356]
Download as PDF
13468
Federal Register / Vol. 88, No. 42 / Friday, March 3, 2023 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1348]
Certain Cabinet X-Ray and Optical
Camera Systems and Components
Thereof; Notice of a Commission
Determination Not To Review an Initial
Determination Terminating the
Investigation Based on Consent Order
Stipulations; Issuance of Consent
Orders; Termination of the
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 4) of the presiding Chief
Administrative Law Judge (‘‘CALJ’’)
terminating the investigation based on
consent order stipulations. The
Commission has entered consent orders
against respondents CompAI Healthcare
(Shenzhen) Co., Ltd., CompAI
Healthcare (Suzhou) Co., Ltd., Kangpai
Medical Technology (Changchun) Co.,
Ltd., Kangpai (Beijing) Medical
Equipment Co., Ltd., and Dilon
Technologies, Inc. The investigation is
terminated.
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
Michael Liberman, Esq., Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
205–2392. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: On
January 3, 2023, the Commission
instituted this investigation under
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, based on a
complaint filed by KUB Technologies,
Inc. of Stratford, Connecticut. 88 FR
113–14 (Jan. 3, 2023). The complaint
alleged a violation of section 337 in the
importation into the United States, the
sale for importation, or the sale within
the United States after importation of
certain cabinet x-ray and optical camera
VerDate Sep<11>2014
19:33 Mar 02, 2023
Jkt 259001
systems and components thereof by
reason of infringement of certain claims
of U.S. Patent No. 10,670,545. Id. at 113.
The complaint also alleged the existence
of a domestic industry.
The notice of investigation named as
respondents the following entities:
CompAI Healthcare (Shenzhen) Co.,
Ltd. of Shenzhen, Guangdong, China
(‘‘CompAI Shenzhen’’), CompAI
Healthcare (Suzhou) Co., Ltd. of
Suzhou, Jiangsu, China (‘‘CompAI
Suzhou’’), Kangpai Medical Technology
(Changchun) Co., Ltd. of Suzhou,
Jiangsu, China (‘‘Kangpai Changchun’’),
Kangpai (Beijing) Medical Equipment
Co., Ltd. of Suzhou, Jiangsu, China
(‘‘Kangpai Beijing’’), and Dilon
Technologies, Inc. of Newport News,
Virginia (‘‘Dilon’’) (collectively,
‘‘Respondents’’). Id. at 114. The
Commission’s Office of Unfair Import
Investigations is not a party to this
investigation. Id.
On January 11, 2023, all of the
Respondents in this investigation—
CompAI Shenzhen, CompAI Suzhou,
Kangpai Changchun, Kangpai Beijing,
and Dilon—filed a motion to terminate
this investigation based on consent
orders and a memorandum in support
thereof. (‘‘Mot.’’). The motion indicates
that it is unopposed. See id. at 1.
On January 31, 2023, the CALJ issued
the subject ID (Order No. 4) granting the
motion. The ID found that the
Respondents represent that ‘‘there are
no other agreements, written or oral,
express or implied between the parties
concerning the subject matter of the
investigation.’’ ID at 1 (citing Mot. at 2;
19 CFR 210.21(c)).
The ID found that, consistent with
Commission Rule 210.21(c)(1)(ii), each
of the Respondents provided a consent
order stipulation and proposed consent
order with the pending motion. Id. at 2–
4. With respect to each of the
Respondents, the ID found that their
respective consent order stipulations
and respective proposed consent orders
conform with Commission Rules
210.21(c)(3) and 210.21(c)(4),
respectively. Id.
Based on the motion papers and the
record as a whole, the ID found that any
effect the proposed consent orders may
have on the statutory public interest
factors does not counsel against entry of
the order. Id. at 5. In addition, the ID
found that termination of the
investigation as to the Respondents by
consent order will preserve Commission
resources and avoid unnecessary
litigation. Id.
The Commission has determined not
to review the subject ID and to issue
consent orders against respondents
CompAI Healthcare (Shenzhen) Co.,
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Ltd., CompAI Healthcare (Suzhou) Co.,
Ltd., Kangpai Medical Technology
(Changchun) Co., Ltd., Kangpai (Beijing)
Medical Equipment Co., Ltd., and Dilon
Technologies, Inc. Accordingly, the
investigation is terminated in its
entirety.
The Commission vote for this
determination took place on February
27, 2023.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, and in Part
210 of the Commission’s Rules of
Practice and Procedure, 19 CFR part
210.
By order of the Commission.
Issued: February 27, 2023.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2023–04356 Filed 3–2–23; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–1332]
Certain Semiconductors and Devices
and Products Containing the Same,
Including Printed Circuit Boards,
Automotive Parts, and Automobiles;
Notice of a Commission Determination
Not To Review an Initial Determination
Terminating the Investigation in Its
Entirety Based on Withdrawal of the
Complaint
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review the presiding administrative law
judge’s (‘‘ALJ’’) initial determination
(‘‘ID’’) (Order No. 16), granting
complainant’s motion to terminate the
investigation based on withdrawal of
the complaint as to all respondents. The
investigation is terminated in its
entirety.
FOR FURTHER INFORMATION CONTACT:
Cathy Chen, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone 202–
205–2392. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
SUMMARY:
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 88, Number 42 (Friday, March 3, 2023)]
[Notices]
[Page 13468]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04356]
[[Page 13468]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1348]
Certain Cabinet X-Ray and Optical Camera Systems and Components
Thereof; Notice of a Commission Determination Not To Review an Initial
Determination Terminating the Investigation Based on Consent Order
Stipulations; Issuance of Consent Orders; Termination of the
Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined not to review an initial determination
(``ID'') (Order No. 4) of the presiding Chief Administrative Law Judge
(``CALJ'') terminating the investigation based on consent order
stipulations. The Commission has entered consent orders against
respondents CompAI Healthcare (Shenzhen) Co., Ltd., CompAI Healthcare
(Suzhou) Co., Ltd., Kangpai Medical Technology (Changchun) Co., Ltd.,
Kangpai (Beijing) Medical Equipment Co., Ltd., and Dilon Technologies,
Inc. The investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Michael Liberman, Esq., Office of the
General Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 205-2392. Copies of non-
confidential documents filed in connection with this investigation may
be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. General information concerning the Commission may
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on
this matter can be obtained by contacting the Commission's TDD terminal
on (202) 205-1810.
SUPPLEMENTARY INFORMATION: On January 3, 2023, the Commission
instituted this investigation under section 337 of the Tariff Act of
1930, as amended, 19 U.S.C. 1337, based on a complaint filed by KUB
Technologies, Inc. of Stratford, Connecticut. 88 FR 113-14 (Jan. 3,
2023). The complaint alleged a violation of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain cabinet x-
ray and optical camera systems and components thereof by reason of
infringement of certain claims of U.S. Patent No. 10,670,545. Id. at
113. The complaint also alleged the existence of a domestic industry.
The notice of investigation named as respondents the following
entities: CompAI Healthcare (Shenzhen) Co., Ltd. of Shenzhen,
Guangdong, China (``CompAI Shenzhen''), CompAI Healthcare (Suzhou) Co.,
Ltd. of Suzhou, Jiangsu, China (``CompAI Suzhou''), Kangpai Medical
Technology (Changchun) Co., Ltd. of Suzhou, Jiangsu, China (``Kangpai
Changchun''), Kangpai (Beijing) Medical Equipment Co., Ltd. of Suzhou,
Jiangsu, China (``Kangpai Beijing''), and Dilon Technologies, Inc. of
Newport News, Virginia (``Dilon'') (collectively, ``Respondents''). Id.
at 114. The Commission's Office of Unfair Import Investigations is not
a party to this investigation. Id.
On January 11, 2023, all of the Respondents in this investigation--
CompAI Shenzhen, CompAI Suzhou, Kangpai Changchun, Kangpai Beijing, and
Dilon--filed a motion to terminate this investigation based on consent
orders and a memorandum in support thereof. (``Mot.''). The motion
indicates that it is unopposed. See id. at 1.
On January 31, 2023, the CALJ issued the subject ID (Order No. 4)
granting the motion. The ID found that the Respondents represent that
``there are no other agreements, written or oral, express or implied
between the parties concerning the subject matter of the
investigation.'' ID at 1 (citing Mot. at 2; 19 CFR 210.21(c)).
The ID found that, consistent with Commission Rule
210.21(c)(1)(ii), each of the Respondents provided a consent order
stipulation and proposed consent order with the pending motion. Id. at
2-4. With respect to each of the Respondents, the ID found that their
respective consent order stipulations and respective proposed consent
orders conform with Commission Rules 210.21(c)(3) and 210.21(c)(4),
respectively. Id.
Based on the motion papers and the record as a whole, the ID found
that any effect the proposed consent orders may have on the statutory
public interest factors does not counsel against entry of the order.
Id. at 5. In addition, the ID found that termination of the
investigation as to the Respondents by consent order will preserve
Commission resources and avoid unnecessary litigation. Id.
The Commission has determined not to review the subject ID and to
issue consent orders against respondents CompAI Healthcare (Shenzhen)
Co., Ltd., CompAI Healthcare (Suzhou) Co., Ltd., Kangpai Medical
Technology (Changchun) Co., Ltd., Kangpai (Beijing) Medical Equipment
Co., Ltd., and Dilon Technologies, Inc. Accordingly, the investigation
is terminated in its entirety.
The Commission vote for this determination took place on February
27, 2023.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and
in Part 210 of the Commission's Rules of Practice and Procedure, 19 CFR
part 210.
By order of the Commission.
Issued: February 27, 2023.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2023-04356 Filed 3-2-23; 8:45 am]
BILLING CODE 7020-02-P